nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—Depressive symptom—Lisinopril—dilated cardiomyopathy	0.0293	0.051	CcSEcCtD
Atomoxetine—Menstruation irregular—Spironolactone—dilated cardiomyopathy	0.0283	0.0493	CcSEcCtD
Atomoxetine—Gastrointestinal symptom NOS—Spironolactone—dilated cardiomyopathy	0.0267	0.0464	CcSEcCtD
Atomoxetine—Epigastric discomfort—Furosemide—dilated cardiomyopathy	0.0162	0.0282	CcSEcCtD
Atomoxetine—Indecainide—SCN5A—dilated cardiomyopathy	0.0158	0.348	CrCbGaD
Atomoxetine—Lethargy—Spironolactone—dilated cardiomyopathy	0.0116	0.0202	CcSEcCtD
Atomoxetine—Pelvic pain—Lisinopril—dilated cardiomyopathy	0.0105	0.0183	CcSEcCtD
Atomoxetine—Drug interaction—Furosemide—dilated cardiomyopathy	0.00919	0.016	CcSEcCtD
Atomoxetine—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00906	0.0158	CcSEcCtD
Atomoxetine—Throat sore—Lisinopril—dilated cardiomyopathy	0.00888	0.0155	CcSEcCtD
Atomoxetine—Oropharyngeal discomfort—Lisinopril—dilated cardiomyopathy	0.0088	0.0153	CcSEcCtD
Atomoxetine—Rhinorrhoea—Lisinopril—dilated cardiomyopathy	0.0079	0.0138	CcSEcCtD
Atomoxetine—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00704	0.0123	CcSEcCtD
Atomoxetine—Drug interaction—Lisinopril—dilated cardiomyopathy	0.0069	0.012	CcSEcCtD
Atomoxetine—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00659	0.0115	CcSEcCtD
Atomoxetine—Thirst—Furosemide—dilated cardiomyopathy	0.0065	0.0113	CcSEcCtD
Atomoxetine—Lethargy—Furosemide—dilated cardiomyopathy	0.00632	0.011	CcSEcCtD
Atomoxetine—Irritability—Furosemide—dilated cardiomyopathy	0.00591	0.0103	CcSEcCtD
Atomoxetine—Urinary retention—Furosemide—dilated cardiomyopathy	0.00589	0.0102	CcSEcCtD
Atomoxetine—Propafenone—SCN5A—dilated cardiomyopathy	0.00568	0.125	CrCbGaD
Atomoxetine—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00537	0.00934	CcSEcCtD
Atomoxetine—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00517	0.009	CcSEcCtD
Atomoxetine—Nasal congestion—Lisinopril—dilated cardiomyopathy	0.0051	0.00888	CcSEcCtD
Atomoxetine—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00501	0.00872	CcSEcCtD
Atomoxetine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00497	0.00866	CcSEcCtD
Atomoxetine—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00494	0.0086	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00483	0.00841	CcSEcCtD
Atomoxetine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00461	0.00802	CcSEcCtD
Atomoxetine—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00461	0.00802	CcSEcCtD
Atomoxetine—Urticaria—Spironolactone—dilated cardiomyopathy	0.00444	0.00773	CcSEcCtD
Atomoxetine—Irritability—Lisinopril—dilated cardiomyopathy	0.00443	0.00772	CcSEcCtD
Atomoxetine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00442	0.0077	CcSEcCtD
Atomoxetine—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00423	0.00736	CcSEcCtD
Atomoxetine—Urethral disorder—Furosemide—dilated cardiomyopathy	0.0042	0.00731	CcSEcCtD
Atomoxetine—Breast disorder—Lisinopril—dilated cardiomyopathy	0.0042	0.00731	CcSEcCtD
Atomoxetine—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00415	0.00723	CcSEcCtD
Atomoxetine—Influenza—Lisinopril—dilated cardiomyopathy	0.00401	0.00699	CcSEcCtD
Atomoxetine—Pruritus—Spironolactone—dilated cardiomyopathy	0.00396	0.00689	CcSEcCtD
Atomoxetine—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00391	0.00681	CcSEcCtD
Atomoxetine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00389	0.00676	CcSEcCtD
Atomoxetine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00383	0.00666	CcSEcCtD
Atomoxetine—Dysuria—Lisinopril—dilated cardiomyopathy	0.00375	0.00654	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00373	0.0065	CcSEcCtD
Atomoxetine—Malnutrition—Furosemide—dilated cardiomyopathy	0.00373	0.00649	CcSEcCtD
Atomoxetine—Dizziness—Spironolactone—dilated cardiomyopathy	0.0037	0.00644	CcSEcCtD
Atomoxetine—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.0037	0.00644	CcSEcCtD
Atomoxetine—Flatulence—Furosemide—dilated cardiomyopathy	0.00367	0.0064	CcSEcCtD
Atomoxetine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00365	0.00636	CcSEcCtD
Atomoxetine—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00363	0.00632	CcSEcCtD
Atomoxetine—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00358	0.00624	CcSEcCtD
Atomoxetine—Depression—Lisinopril—dilated cardiomyopathy	0.00357	0.00621	CcSEcCtD
Atomoxetine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00356	0.00619	CcSEcCtD
Atomoxetine—Rash—Spironolactone—dilated cardiomyopathy	0.00353	0.00614	CcSEcCtD
Atomoxetine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00352	0.00613	CcSEcCtD
Atomoxetine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00351	0.00612	CcSEcCtD
Atomoxetine—Headache—Spironolactone—dilated cardiomyopathy	0.0035	0.0061	CcSEcCtD
Atomoxetine—Agitation—Furosemide—dilated cardiomyopathy	0.00343	0.00596	CcSEcCtD
Atomoxetine—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00336	0.00585	CcSEcCtD
Atomoxetine—Vertigo—Furosemide—dilated cardiomyopathy	0.00335	0.00583	CcSEcCtD
Atomoxetine—Nausea—Spironolactone—dilated cardiomyopathy	0.00332	0.00578	CcSEcCtD
Atomoxetine—Hallucination—Lisinopril—dilated cardiomyopathy	0.0032	0.00557	CcSEcCtD
Atomoxetine—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00317	0.00552	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00315	0.00549	CcSEcCtD
Atomoxetine—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00315	0.00548	CcSEcCtD
Atomoxetine—Orphenadrine—SCN5A—dilated cardiomyopathy	0.00313	0.0689	CrCbGaD
Atomoxetine—Dry mouth—Furosemide—dilated cardiomyopathy	0.0031	0.0054	CcSEcCtD
Atomoxetine—Shock—Furosemide—dilated cardiomyopathy	0.00299	0.00521	CcSEcCtD
Atomoxetine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00298	0.00519	CcSEcCtD
Atomoxetine—Flushing—Lisinopril—dilated cardiomyopathy	0.00298	0.00519	CcSEcCtD
Atomoxetine—Skin disorder—Furosemide—dilated cardiomyopathy	0.00296	0.00515	CcSEcCtD
Atomoxetine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00294	0.00512	CcSEcCtD
Atomoxetine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00292	0.00508	CcSEcCtD
Atomoxetine—Anorexia—Furosemide—dilated cardiomyopathy	0.0029	0.00505	CcSEcCtD
Atomoxetine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.0029	0.00504	CcSEcCtD
Atomoxetine—Chills—Lisinopril—dilated cardiomyopathy	0.00288	0.00502	CcSEcCtD
Atomoxetine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00281	0.0049	CcSEcCtD
Atomoxetine—Malnutrition—Lisinopril—dilated cardiomyopathy	0.0028	0.00487	CcSEcCtD
Atomoxetine—Flatulence—Lisinopril—dilated cardiomyopathy	0.00276	0.0048	CcSEcCtD
Atomoxetine—Tension—Lisinopril—dilated cardiomyopathy	0.00274	0.00478	CcSEcCtD
Atomoxetine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00274	0.00477	CcSEcCtD
Atomoxetine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00273	0.00476	CcSEcCtD
Atomoxetine—Nervousness—Lisinopril—dilated cardiomyopathy	0.00272	0.00473	CcSEcCtD
Atomoxetine—Back pain—Lisinopril—dilated cardiomyopathy	0.00271	0.00471	CcSEcCtD
Atomoxetine—Somnolence—Furosemide—dilated cardiomyopathy	0.0027	0.00471	CcSEcCtD
Atomoxetine—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00269	0.00468	CcSEcCtD
Atomoxetine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00264	0.0046	CcSEcCtD
Atomoxetine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00264	0.00459	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00263	0.00457	CcSEcCtD
Atomoxetine—Fatigue—Furosemide—dilated cardiomyopathy	0.00262	0.00457	CcSEcCtD
Atomoxetine—Tremor—Lisinopril—dilated cardiomyopathy	0.00262	0.00456	CcSEcCtD
Atomoxetine—Pain—Furosemide—dilated cardiomyopathy	0.0026	0.00453	CcSEcCtD
Atomoxetine—Constipation—Furosemide—dilated cardiomyopathy	0.0026	0.00453	CcSEcCtD
Atomoxetine—Vertigo—Lisinopril—dilated cardiomyopathy	0.00251	0.00438	CcSEcCtD
Atomoxetine—Syncope—Lisinopril—dilated cardiomyopathy	0.00251	0.00437	CcSEcCtD
Atomoxetine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00251	0.00437	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00249	0.00433	CcSEcCtD
Atomoxetine—Palpitations—Lisinopril—dilated cardiomyopathy	0.00247	0.0043	CcSEcCtD
Atomoxetine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00246	0.00428	CcSEcCtD
Atomoxetine—Ephedrine—ADRB2—dilated cardiomyopathy	0.00244	0.0538	CrCbGaD
Atomoxetine—Cough—Lisinopril—dilated cardiomyopathy	0.00244	0.00425	CcSEcCtD
Atomoxetine—Urticaria—Furosemide—dilated cardiomyopathy	0.00242	0.00421	CcSEcCtD
Atomoxetine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.0024	0.00419	CcSEcCtD
Atomoxetine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.0024	0.00419	CcSEcCtD
Atomoxetine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00238	0.00415	CcSEcCtD
Atomoxetine—Myalgia—Lisinopril—dilated cardiomyopathy	0.00238	0.00415	CcSEcCtD
Atomoxetine—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00238	0.00415	CcSEcCtD
Atomoxetine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00237	0.00413	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00236	0.00412	CcSEcCtD
Atomoxetine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00233	0.00405	CcSEcCtD
Atomoxetine—Infection—Lisinopril—dilated cardiomyopathy	0.00227	0.00395	CcSEcCtD
Atomoxetine—Propafenone—ADRB1—dilated cardiomyopathy	0.00226	0.0498	CrCbGaD
Atomoxetine—Shock—Lisinopril—dilated cardiomyopathy	0.00225	0.00391	CcSEcCtD
Atomoxetine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00223	0.00388	CcSEcCtD
Atomoxetine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00222	0.00386	CcSEcCtD
Atomoxetine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00221	0.00384	CcSEcCtD
Atomoxetine—Pseudoephedrine—ADRB1—dilated cardiomyopathy	0.0022	0.0485	CrCbGaD
Atomoxetine—Asthenia—Furosemide—dilated cardiomyopathy	0.00218	0.0038	CcSEcCtD
Atomoxetine—Anorexia—Lisinopril—dilated cardiomyopathy	0.00218	0.00379	CcSEcCtD
Atomoxetine—Pruritus—Furosemide—dilated cardiomyopathy	0.00215	0.00375	CcSEcCtD
Atomoxetine—Pseudoephedrine—TNF—dilated cardiomyopathy	0.00209	0.046	CrCbGaD
Atomoxetine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00208	0.00362	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00208	0.00362	CcSEcCtD
Atomoxetine—Insomnia—Lisinopril—dilated cardiomyopathy	0.00206	0.00359	CcSEcCtD
Atomoxetine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00205	0.00357	CcSEcCtD
Atomoxetine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00203	0.00353	CcSEcCtD
Atomoxetine—Dizziness—Furosemide—dilated cardiomyopathy	0.00201	0.0035	CcSEcCtD
Atomoxetine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00201	0.0035	CcSEcCtD
Atomoxetine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00198	0.00345	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00197	0.00343	CcSEcCtD
Atomoxetine—Fatigue—Lisinopril—dilated cardiomyopathy	0.00197	0.00343	CcSEcCtD
Atomoxetine—Constipation—Lisinopril—dilated cardiomyopathy	0.00195	0.0034	CcSEcCtD
Atomoxetine—Pain—Lisinopril—dilated cardiomyopathy	0.00195	0.0034	CcSEcCtD
Atomoxetine—Vomiting—Furosemide—dilated cardiomyopathy	0.00193	0.00337	CcSEcCtD
Atomoxetine—Rash—Furosemide—dilated cardiomyopathy	0.00192	0.00334	CcSEcCtD
Atomoxetine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00192	0.00334	CcSEcCtD
Atomoxetine—Headache—Furosemide—dilated cardiomyopathy	0.00191	0.00332	CcSEcCtD
Atomoxetine—Diphenhydramine—SLC22A5—dilated cardiomyopathy	0.00191	0.042	CrCbGaD
Atomoxetine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00188	0.00328	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00187	0.00325	CcSEcCtD
Atomoxetine—Pseudoephedrine—ADRB2—dilated cardiomyopathy	0.00185	0.0408	CrCbGaD
Atomoxetine—Urticaria—Lisinopril—dilated cardiomyopathy	0.00181	0.00316	CcSEcCtD
Atomoxetine—Nausea—Furosemide—dilated cardiomyopathy	0.00181	0.00315	CcSEcCtD
Atomoxetine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.0018	0.00314	CcSEcCtD
Atomoxetine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.0018	0.00314	CcSEcCtD
Atomoxetine—Desipramine—SLC22A5—dilated cardiomyopathy	0.0017	0.0374	CrCbGaD
Atomoxetine—Asthenia—Lisinopril—dilated cardiomyopathy	0.00164	0.00285	CcSEcCtD
Atomoxetine—Pruritus—Lisinopril—dilated cardiomyopathy	0.00161	0.00281	CcSEcCtD
Atomoxetine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00156	0.00272	CcSEcCtD
Atomoxetine—Propranolol—ADRB1—dilated cardiomyopathy	0.00155	0.0341	CrCbGaD
Atomoxetine—Dizziness—Lisinopril—dilated cardiomyopathy	0.00151	0.00263	CcSEcCtD
Atomoxetine—Vomiting—Lisinopril—dilated cardiomyopathy	0.00145	0.00253	CcSEcCtD
Atomoxetine—Rash—Lisinopril—dilated cardiomyopathy	0.00144	0.00251	CcSEcCtD
Atomoxetine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00144	0.0025	CcSEcCtD
Atomoxetine—Headache—Lisinopril—dilated cardiomyopathy	0.00143	0.00249	CcSEcCtD
Atomoxetine—Nausea—Lisinopril—dilated cardiomyopathy	0.00136	0.00236	CcSEcCtD
Atomoxetine—Phenoxybenzamine—ADRB2—dilated cardiomyopathy	0.00132	0.0291	CrCbGaD
Atomoxetine—Propranolol—ADRB2—dilated cardiomyopathy	0.0013	0.0287	CrCbGaD
Atomoxetine—Desipramine—ADRB1—dilated cardiomyopathy	0.00117	0.0258	CrCbGaD
Atomoxetine—Desipramine—ADRB2—dilated cardiomyopathy	0.000986	0.0217	CrCbGaD
Atomoxetine—HTR1D—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000598	0.00157	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000593	0.00156	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00059	0.00155	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000585	0.00154	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.000583	0.00153	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000582	0.00153	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000581	0.00153	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00058	0.00153	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.00058	0.00153	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000564	0.00148	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000562	0.00148	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000562	0.00148	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000554	0.00146	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000551	0.00145	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.00055	0.00145	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.00055	0.00145	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000528	0.00139	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000527	0.00139	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000522	0.00137	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000514	0.00135	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000511	0.00134	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00051	0.00134	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000506	0.00133	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000504	0.00133	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000503	0.00132	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.0005	0.00131	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000497	0.00131	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000495	0.0013	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000492	0.0013	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000492	0.0013	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000488	0.00128	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000484	0.00127	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000478	0.00126	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000475	0.00125	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000474	0.00125	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000473	0.00124	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000472	0.00124	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000472	0.00124	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000462	0.00121	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000459	0.00121	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000458	0.0012	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000443	0.00117	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000432	0.00114	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000428	0.00112	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000428	0.00112	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000423	0.00111	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00041	0.00108	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00041	0.00108	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000401	0.00105	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000399	0.00105	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000398	0.00105	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000385	0.00101	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000382	0.001	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000379	0.000996	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000378	0.000994	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000378	0.000994	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000375	0.000986	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000375	0.000986	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000367	0.000966	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000367	0.000966	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000362	0.000952	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000359	0.000945	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000359	0.000944	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000352	0.000925	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000351	0.000924	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00035	0.00092	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000349	0.000919	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000349	0.000917	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000345	0.000906	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000343	0.000902	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000343	0.000902	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000341	0.000898	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000341	0.000896	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000341	0.000896	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00034	0.000895	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000338	0.000888	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000333	0.000877	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000333	0.000877	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000331	0.000869	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000329	0.000865	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000328	0.000862	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000319	0.000839	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000317	0.000833	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000312	0.00082	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000311	0.000819	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.00031	0.000815	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000309	0.000813	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000307	0.000806	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000304	0.000799	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.0003	0.00079	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AGT—dilated cardiomyopathy	0.000297	0.000782	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—RAF1—dilated cardiomyopathy	0.000293	0.00077	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000291	0.000764	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000288	0.000758	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000285	0.000749	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000282	0.000743	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000278	0.000732	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000278	0.000732	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000276	0.000725	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000274	0.000719	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000268	0.000704	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	0.000267	0.000702	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000266	0.000701	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000264	0.000694	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000262	0.000689	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000259	0.00068	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000256	0.000674	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000253	0.000665	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000253	0.000665	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	0.000251	0.00066	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000251	0.000659	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00025	0.000658	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000248	0.000653	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000246	0.000646	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000243	0.00064	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000242	0.000636	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000242	0.000636	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.00024	0.000632	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.00024	0.00063	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000235	0.000618	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000231	0.000609	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	0.000231	0.000607	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000228	0.0006	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000228	0.000598	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	0.000227	0.000597	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000227	0.000596	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000225	0.000591	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000225	0.000591	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000222	0.000583	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000219	0.000577	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000219	0.000577	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000218	0.000572	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000214	0.000563	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000214	0.000563	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000212	0.000559	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	0.000209	0.000549	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000208	0.000547	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000206	0.000543	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000204	0.000538	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000204	0.000537	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000203	0.000534	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000203	0.000534	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000203	0.000533	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000203	0.000533	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000201	0.000529	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000201	0.000529	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000199	0.000523	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000198	0.00052	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000197	0.000518	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000197	0.000518	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000195	0.000514	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000194	0.000511	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000194	0.000511	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000193	0.000507	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000189	0.000497	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000188	0.000496	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000187	0.000492	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000186	0.000489	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000186	0.000488	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000184	0.000485	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000184	0.000485	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000183	0.000482	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000183	0.00048	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000181	0.000476	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AGT—dilated cardiomyopathy	0.00018	0.000475	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000178	0.000467	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000177	0.000466	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000176	0.000464	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000169	0.000444	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000168	0.000442	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000161	0.000422	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00016	0.000421	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000158	0.000414	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000157	0.000414	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000156	0.00041	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000155	0.000407	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000151	0.000398	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000151	0.000397	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000151	0.000396	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000149	0.000393	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000149	0.000393	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000148	0.000389	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000147	0.000386	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000146	0.000384	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000144	0.000378	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000143	0.000376	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000142	0.000372	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000139	0.000365	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000138	0.000364	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000137	0.00036	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000137	0.00036	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000137	0.000359	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000135	0.000355	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000134	0.000353	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000131	0.000344	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.00013	0.000341	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.00013	0.000341	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000129	0.000339	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000128	0.000336	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000127	0.000334	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000126	0.000332	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000125	0.000329	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000124	0.000327	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000123	0.000325	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000121	0.000319	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000121	0.000317	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000119	0.000312	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000117	0.000307	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000115	0.000302	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000115	0.000302	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000114	0.0003	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000112	0.000293	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AGT—dilated cardiomyopathy	0.00011	0.000288	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000109	0.000286	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AGT—dilated cardiomyopathy	0.000109	0.000286	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AGT—dilated cardiomyopathy	0.000107	0.00028	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.97e-05	0.000262	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.49e-05	0.00025	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.46e-05	0.000249	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.36e-05	0.000246	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EGFR—dilated cardiomyopathy	8.84e-05	0.000232	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EGFR—dilated cardiomyopathy	8.77e-05	0.000231	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	8.59e-05	0.000226	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RAC1—dilated cardiomyopathy	8.46e-05	0.000222	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	8.24e-05	0.000217	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	8.13e-05	0.000214	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AGT—dilated cardiomyopathy	8.08e-05	0.000212	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—RAF1—dilated cardiomyopathy	7.61e-05	0.0002	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—RAF1—dilated cardiomyopathy	7.56e-05	0.000199	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—RAF1—dilated cardiomyopathy	7.4e-05	0.000195	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RAC1—dilated cardiomyopathy	7.34e-05	0.000193	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGT—dilated cardiomyopathy	7.02e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.51e-05	0.000171	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	6.17e-05	0.000162	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	6.01e-05	0.000158	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	5.67e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.65e-05	0.000149	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—RAF1—dilated cardiomyopathy	5.61e-05	0.000147	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	5.52e-05	0.000145	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	5.41e-05	0.000142	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—dilated cardiomyopathy	5.22e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—dilated cardiomyopathy	5.18e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—dilated cardiomyopathy	5.07e-05	0.000133	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	4.97e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RAF1—dilated cardiomyopathy	4.87e-05	0.000128	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—dilated cardiomyopathy	3.84e-05	0.000101	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	3.71e-05	9.75e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	3.61e-05	9.5e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—dilated cardiomyopathy	3.34e-05	8.78e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	3.25e-05	8.55e-05	CbGpPWpGaD
